openPR Logo
Press release

Lyme Disease Diagnostic Market to Record an Exponential CAGR by 2019

07-05-2018 08:17 PM CET | Health & Medicine

Press release from: Transparency Market Research

Lyme Disease Diagnostic Market to Record an Exponential CAGR

Lyme disease is an infectious disease caused by bacterial species borrelia. It is a tick borne disease caused by the transmission to humans by the bite of infected ticks. Patients infected with lyme disease suffer from symptoms such as fever, depression, fatigue and skin rashes. If the disease is diagnosed at an early stage then it can be treated with antibiotics. However, if the disease is left untreated then it affects heart, joint and central nervous system and might become a cause for death.

The Lyme Disease Diagnostic Market is segmented on the basis of diagnostic tests, emerging diagnostic technologies and end users. Emerging technologies segment comprises of molecular diagnostics, monoclonal antibodies, immunoassays, differential light scattering, liposomes, artificial intelligence, flow cytometry, information technology, diagnostic imaging, gel microdroplets, chromatography and others. The endusers segment of the market includes hospitals, commercial/private labs, public health labs and physicians office. Various forms of laboratory testing for lyme disease are available and among them most widely used are serological test. Among the serological tests most commonly used are ELISA and Western Blot. Moreover, some laboratories offer tests that include urine antigen tests, lymphocytic transformation test, immunofluorescent staining and PCR tests. New lyme disease diagnostic tests are being developed that are particularly suited for diagnosis of chronic lyme infection using blood sample. These tests overcome the accuracy problems which were encountered in serology based tests.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1658

Globally North America accounts for the largest share of the market owing to the most common tick disease in the U.S. According to the Center for Disease Control and Prevention (CDC) in 2011, 24,364 people were diagnosed with lyme disease in the United States. The European and Asian markets are also expected to emerge in near future owing to increase in patients infected with lyme diseases.

Some of the key players engaged in manufacturing of diagnostic tests include Abbott Laboratories, Affymetrix, Inc., Bio-Rad, Roche Diagnostics among others.

View Report -

https://www.transparencymarketresearch.com/lyme-disease-diagnostic.html

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lyme Disease Diagnostic Market to Record an Exponential CAGR by 2019 here

News-ID: 1112469 • Views:

More Releases from Transparency Market Research

Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / By Function | Europe • North America • Asia Pacific
Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / …
The global functional coffee market was valued at US$ 21.5 Bn in 2024 and is projected to reach US$ 48.1 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2035. This steady growth trajectory reflects the strong convergence of coffee consumption habits with rising demand for functional and wellness-oriented beverages. Functional coffee has transitioned from a niche category to a mainstream product offering,
Global Electric Face Cleanser Market Poised for Robust Growth, projected to Reach USD 23.6 Billion by 2036 | Transparency Market Research
Global Electric Face Cleanser Market Poised for Robust Growth, projected to Reac …
The global electric face cleanser market is witnessing a transformative growth phase as consumers increasingly integrate advanced skincare technologies into their daily routines. Valued at USD 9.8 billion in 2025, the market is projected to expand significantly and reach USD 23.6 billion by 2036, growing at a healthy compound annual growth rate (CAGR) of 8.6% from 2026 to 2036. This growth trajectory underscores the rising importance of personal care technology,
Asthma and COPD Drugs Market to Reach US$ 82.2 Billion by 2036, Growing at 5.7% CAGR Driven by Rising Respiratory Disease Burden
Asthma and COPD Drugs Market to Reach US$ 82.2 Billion by 2036, Growing at 5.7% …
The global asthma and COPD drugs market demonstrated strong fundamentals in 2025, with a valuation of US$ 44.7 Bn, reflecting the essential and recurring nature of respiratory therapeutics. Supported by a growing patient base and continuous pharmaceutical innovation, the market is projected to reach US$ 82.2 Bn by 2036, expanding at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2036. This growth trajectory highlights the increasing reliance on
Low-Alcohol Beverages Market Outlook 2035: Global Industry Set to Expand from US$ 2.1 Bn to US$ 4.6 Bn by 2035 at 7.5% CAGR
Low-Alcohol Beverages Market Outlook 2035: Global Industry Set to Expand from US …
The global low-alcohol beverages market is undergoing a structural transformation as consumers increasingly prioritize health, moderation, and mindful drinking without sacrificing taste or social experiences. Valued at US$ 2.1 billion in 2024, the market is projected to reach US$ 4.6 billion by 2035, expanding at a healthy CAGR of 7.5% from 2025 to 2035. This sustained growth reflects changing lifestyle preferences, generational shifts in alcohol consumption, and continuous innovation by

All 5 Releases


More Releases for Lyme

Lyme Disease Diagnostics Market Projected to Show Strong Growth
Advance Market Analytics published a new research publication on "Lyme Disease Diagnostics Market Insights, to 2033" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Lyme Disease Diagnostics market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample
Lyme Disease - Drug Pipeline Landscape, 2022
Lyme disease is a tick-borne infection caused by four main species of bacteria Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii and Borrelia garinii. The disease is characterized by skin rash. Early signs and symptoms of Lyme disease include rash and other symptoms like fever, chills, fatigue, body aches, and swollen lymph nodes. Later symptoms include erythema migrans, joint pain and other neurological problems. To know more about Lyme Disease - Drug Pipeline ,
Lyme Disease - Drug Pipeline Landscape, 2022 | Global Insight Services
Lyme disease is a tick-borne infection caused by four main species of bacteria Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii and Borrelia garinii. The disease is characterized by skin rash. Early signs and symptoms of Lyme disease include rash and other symptoms like fever, chills, fatigue, body aches, and swollen lymph nodes. Later symptoms include erythema migrans, joint pain and other neurological problems. Diagnosis of Lyme disease involves lab tests to
Lyme Disease Vaccines - Are They Effective?| Valneva, GlaxoSmithKline Plc.
There is currently no Lyme disease vaccine available. LYMERix®, the only vaccine previously marketed in the United States, was withdrawn from the market in 2002 due to a lack of consumer demand. The vaccine's effectiveness deteriorates over time. Lyme Disease Vaccines Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing
Lyme Disease Therapeutics Market Size Statistics, Facts and Figures
Global Lyme Disease Therapeutics Market: Overview Lyme disease is a contagious disease caused by a bacterium species called Borrelia burgdorferi. It is a tick-borne disease caused by transmission of bacteria to humans through the bite of infected ticks. Common indications of Lyme disease include flu-like symptoms, depression, fatigue, and expanding, circular, reddish skin rashes. View Report : https://www.transparencymarketresearch.com/lyme-disease-therapeutics-market.html If left untreated, these symptoms may worsen and can lead to partial or complete
Lyme Disease Diagnostic Testing Market
The report presents a detailed analysis of the Lyme disease diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Lyme disease definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Commercial/Private Labs